WeTrials
Recruiting

RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC

What is this study?

This study is testing a new cancer medicine called daraxonrasib to see if it works better than standard chemotherapy for a specific type of advanced lung cancer. Researchers want to find safer and more effective treatment options for patients whose cancer has grown or spread.

Who can participate?

You might be able to join if you are 18 or older, have a confirmed diagnosis of advanced lung cancer that has spread, and are generally active. You also need to have healthy organ function based on blood tests and cannot have received certain previous treatments.

What will happen?

Participants will be randomly assigned to receive either the new study drug or standard chemotherapy called docetaxel. Your health team will closely monitor your safety, side effects, and how your tumor responds to the treatment throughout the study.

Where and when?

The study is currently active and recruiting patients at several locations across the United States, including sites in Alabama, California, and Connecticut.

Key Points
  • 1Testing an investigational medicine called daraxonrasib against standard chemotherapy
  • 2Open to adults with advanced lung cancer that has spread
  • 3Currently recruiting participants at multiple locations in the United States

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung CancerNSCLCNSCLC (Non-small Cell Lung Carcinoma)NSCLC (Advanced Non-small Cell Lung Cancer)

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.